Amarin Corp Plc (AMRN)

[Lrich]

Progressing VASCEPA® development in Europe towards expected approval in early 2021

Please, explain this statement, direct from the Amarin PR then. I see it stating "early 2021." This is a change from the prior ER which stated:

In Europe, the marketing authorization application for VASCEPA with the European Medicines Agency, or EMA, is undergoing review with an approval recommendation anticipated by Amarin near the end of 2020

I'd have expected them to have not changed the phrasing from "near the end of 2020" to "early 2021" if they still expected it by EOY.